David Walker

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs

W. Nelson, S. Yegnasubramanian, D. Esopi, 2019, Oncotarget.

Re: Decision Making in Prostate Cancer Screening Using Decision Aids vs Usual Care: A Randomized Clinical Trial

W. Isaacs, M. Halushka, J. Hicks, 2014 .

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Bie M. P. Verbist, U. Philippar, T. Graubert, 2021, Molecular Cancer Therapeutics.

Tracking the clonal origin of lethal prostate cancer.

W. Isaacs, M. Halushka, J. Hicks, 2013, The Journal of clinical investigation.

Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2

W. Nelson, S. Yegnasubramanian, N. Wyhs, 2014, Journal of biomolecular screening.

Abstract 5390: Development of a high-throughput screening assay to identify UHRF1 inhibitors via time-resolved fluorescence resonance energy transfer (TR-FRET)

S. Yegnasubramanian, N. Wyhs, H. Giovinazzo, 2014 .